Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL

Purpose We examined the association between high doses of Epoetin alfa (EPO), which are used to raise and maintain hemoglobin (Hb) levels within target ranges for hemodialysis patients, and short‐term mortality risk using multivariable regression and an instrumental variable (IV) analysis. Methods W...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacoepidemiology and drug safety 2009-10, Vol.18 (10), p.932-940
Main Authors: Bradbury, Brian D., Do, Thy P., Winkelmayer, Wolfgang C., Critchlow, Cathy W., Brookhart, M. Alan
Format: Article
Language:English
Subjects:
Aged
anemia
Anemia - blood
Anemia - drug therapy
Anemia - etiology
Anemia - mortality
Biomarkers - blood
Confounding Factors (Epidemiology)
confounding-by-indication
Epoetin Alfa
Erythropoietin - administration & dosage
Erythropoietin - adverse effects
Female
Hematinics - administration & dosage
Hematinics - adverse effects
hemodialysis
Hemoglobins - metabolism
Humans
Least-Squares Analysis
Linear Models
Male
Middle Aged
mortality
Recombinant Proteins
Renal Dialysis - adverse effects
Renal Dialysis - mortality
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose We examined the association between high doses of Epoetin alfa (EPO), which are used to raise and maintain hemoglobin (Hb) levels within target ranges for hemodialysis patients, and short‐term mortality risk using multivariable regression and an instrumental variable (IV) analysis. Methods We identified 32 734 patients receiving hemodialysis in 786 facilities from a large US dialysis provider between July 2000 and March 2002 who received care for >4 consecutive months, and had an Hb 
ISSN:1053-8569
1099-1557
DOI:10.1002/pds.1799